Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation

Siddharth Sood, Craig Haifer, Lijia Yu, Julie Pavlovic, Paul J. Gow, Robert M. Jones, Kumar Visvanathan, Peter W. Angus, Adam G. Testro – 20 July 2015 – Cytomegalovirus (CMV) can reactivate following liver transplantation. Management of patients currently considered low risk based on pretransplant serology remains contentious, with universal prophylaxis and preemptive strategies suffering from significant deficiencies.

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis

Siddharth Singh, Rohan Khera, Alina M. Allen, M. Hassan Murad, Rohit Loomba – 18 July 2015 – We performed a Bayesian network meta‐analysis combining direct and indirect treatment comparisons to assess the comparative effectiveness of pharmacological agents for the treatment of nonalcoholic steatohepatitis (NASH). Through systematic literature review, we identified nine randomized, controlled trials (RCTs) including 964 patients with biopsy‐proven NASH, comparing vitamin E, thiazolidinediones (TZDs), pentoxifylline, or obeticholic acid to one another or placebo.

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis

Siddharth Singh, Rohan Khera, Alina M. Allen, M. Hassan Murad, Rohit Loomba – 18 July 2015 – We performed a Bayesian network meta‐analysis combining direct and indirect treatment comparisons to assess the comparative effectiveness of pharmacological agents for the treatment of nonalcoholic steatohepatitis (NASH). Through systematic literature review, we identified nine randomized, controlled trials (RCTs) including 964 patients with biopsy‐proven NASH, comparing vitamin E, thiazolidinediones (TZDs), pentoxifylline, or obeticholic acid to one another or placebo.

RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma

Huey‐Huey Chua, Daw‐Jen Tsuei, Po‐Huang Lee, Yung‐Ming Jeng, Jean Lu, Jia‐Feng Wu, De‐Shiuan Su, Ya‐Hui Chen, Chin‐Sung Chien, Pei‐Chi Kao, Chien‐Nan Lee, Rey‐Heng Hu, Yen‐Hsuan Ni, Mei‐Hwei Chang – 16 July 2015 – Male predominance of hepatocellular carcinoma (HCC) occurs particularly among young children aged 6‐9 years, indicative of a possible role of the Y chromosome–encoded oncogene in addition to an androgenic effect.

A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation

Muhammed Yuksel, Yipeng Wang, Ningwen Tai, Jian Peng, Junhua Guo, Kathie Beland, Pascal Lapierre, Chella David, Fernando Alvarez, Isabelle Colle, Huiping Yan, Giorgina Mieli‐Vergani, Diego Vergani, Yun Ma, Li Wen – 16 July 2015 – Autoimmune hepatitis (AIH) in humans is a severe inflammatory liver disease characterized by interface hepatitis, the presence of circulating autoantibodies, and hyper‐gammaglobulinemia. There are two types of AIH, type 1 (AIH‐1) and type 2 (AIH‐2), characterized by distinct autoimmune serology.

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

Ezequiel Rodriguez, Gustavo Henrique Pereira, Elsa Solà, Chiara Elia, Rogelio Barreto, Elisa Pose, Jordi Colmenero, Javier Fernandez, Miquel Navasa, Vicente Arroyo, Pere Ginès – 15 July 2015 – There is little information on the effects of treatment with vasoconstrictors plus albumin in patients with type 2 hepatorenal syndrome (HRS), particularly those awaiting liver transplantation (LT). This study reports the effects of treatment of type 2 HRS in patients on the waiting list for LT. We included 56 patients with type 2 HRS who were awaiting LT.

Subscribe to